The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody ...
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...
Today on Louisiana Considered, we learn why the state’s reserve funds are currently flush with cash — but may not stay that ...
Imaging studies of more than 27,000 adults link a healthier thymus on CT scans with a longer life and lower risks of ...
Plus: Parkland Health selected for Nation Workforce Well-Being Initiative, Plano-based Percipio Health joins American Heart ...
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...
This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial ...
Researchers developed an implant that boosts immune cell activity, enabling stronger, longer-lasting cancer responses in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results